KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) EBITDA: 2011-2024

Historic EBITDA for Esperion Therapeutics (ESPR) over the last 14 years, with Dec 2024 value amounting to -$51.7 million.

  • Esperion Therapeutics' EBITDA fell 6.13% to -$31.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$105.8 million, marking a year-over-year decrease of 21.97%. This contributed to the annual value of -$51.7 million for FY2024, which is 75.27% up from last year.
  • Per Esperion Therapeutics' latest filing, its EBITDA stood at -$51.7 million for FY2024, which was up 75.27% from -$209.2 million recorded in FY2023.
  • In the past 5 years, Esperion Therapeutics' EBITDA ranged from a high of -$51.7 million in FY2024 and a low of -$269.1 million during FY2021.
  • Over the past 3 years, Esperion Therapeutics' median EBITDA value was -$209.2 million (recorded in 2023), while the average stood at -$164.9 million.
  • In the last 5 years, Esperion Therapeutics' EBITDA plummeted by 87.46% in 2021 and then soared by 75.27% in 2024.
  • Over the past 5 years, Esperion Therapeutics' EBITDA (Yearly) stood at -$143.6 million in 2020, then crashed by 87.46% to -$269.1 million in 2021, then increased by 13.19% to -$233.6 million in 2022, then grew by 10.44% to -$209.2 million in 2023, then skyrocketed by 75.27% to -$51.7 million in 2024.